In chronic myeloid leukemia, for instance, tyrosine kinase inhibitors like imatinib might become resistant due to mutations in the tyrosine kinase domain of BCR-ABL. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.